PHILADELPHIA, Aug. 3 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK - News), one of the world’s largest vaccine manufacturers, today announced that HHS has placed another order to purchase bulk H5N1 antigen for the US national stockpile of pre-pandemic vaccines. The company also announced the start of the first North American pre-pandemic vaccine trials in the company’s global pre-pandemic influenza program.
